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During endochondral ossification, small, immature
chondrocytes enlarge to form hypertrophic chondro-
cytes, which express collagen X. In this work, we
demonstrate that FoxA factors are induced during
chondrogenesis, bind to conserved binding sites
in the collagen X enhancer, and can promote the
expression of a collagen X-luciferase reporter in
both chondrocytes and fibroblasts. In addition, we
demonstrate by both gain- and loss-of-function anal-
yses that FoxA factors play a crucial role in driving
the expression of both endogenous collagen X and
other hypertrophic chondrocyte-specific genes.
Mice engineered to lack expression of both FoxA2
and FoxA3 in their chondrocytes display defects in
chondrocyte hypertrophy, alkaline phosphatase
expression, and mineralization in their sternebrae
and, in addition, exhibit postnatal dwarfism that is
coupled to significantly decreased expression of
both collagen X and MMP13 in their growth plates.
Our findings indicate that FoxA family members are
crucial regulators of the hypertrophic chondrocyte
differentiation program.
INTRODUCTION
The axial and appendicular skeleton is formed by a process
termed endochondral ossification. During this process, mesen-
chymal cells aggregate to form cartilage condensations consist-
ing of immature chondrocytes. Cells lying within the central
regions of the cartilage undergo a further differentiation process
(hypertrophy), withdrawing from the cell cycle, enlarging their
size, and initiating synthesis of a new extracellular matrix con-
taining collagen X. Chondrocyte hypertrophy is largely respon-
sible for about 60% of skeletal growth, whereas 30% is due to
matrix deposition and about 10% is due to cellular proliferation
(Wilsman et al., 1996). The early steps of chondrogenesis,
including mesenchymal condensation and expression of chon-Devedrocyte-specific extracellular matrix proteins, are critically
dependent upon Sox-family transcription factors, including
Sox9, Sox5, and Sox6 (de Crombrugghe et al., 2001; Lefebvre,
2002). In contrast, the process of chondrocyte hypertrophy is
regulated by the Runx family of transcription factors. Runx2
and Runx3 are expressed in chondrocytes as they initiate
differentiation, and loss of these factors (in genetically engi-
neeredmice) severely delays or blocks chondrocyte hypertrophy
in a number of developing bones (Inada et al., 1999; Kim et al.,
1999; Yoshida et al., 2004). Similarly, conditional deletion of
Runx1 in the developing skeleton results in delay of chondrocyte
hypertrophy and ossification in the axial skeletal elements,
whereas the appendicular ones are largely unaffected (Kimura
et al., 2010). Conversely, ectopic expression of Runx2 in
immature chondrocytes drives premature cellular maturation
and induces expression of collagen X and other hypertrophic
markers, both in vivo (Stricker et al., 2002; Takeda et al., 2001;
Ueta et al., 2001) and in vitro (Enomoto et al., 2000). In addition
to Runx family members, MEF2C and MEF2D also play a critical
role in modulating chondrocyte hypertrophy. They do so either
directly, by controlling expression of various differentiation
markers (i.e., Indian Hedgehog, PTHrP Receptor, collagen X),
or indirectly, by promoting Runx2 expression (Arnold et al.,
2007).
Besides their role in promoting cartilage hypertrophy, both
Runx and MEF2 families play critical roles in regulating either
osteocyte formation (Runx2) (Komori et al., 1997) or osteocyte
homeostasis (MEF2) (Leupin et al., 2007). Because both hyper-
trophic cartilage and osteocytes share a common precursor
cell (Akiyama et al., 2005) and a common set of transcriptional
regulators (i.e., Runx2 and MEF2), it seems likely that these
two cell types may differentially express other regulators to
account for their phenotypic differences. To investigate whether
this phenotypic divergence can be explained by the existence of
lineage-specific cofactors, we forced expression of Runx2 in
undifferentiated mesenchymal progenitor cells (i.e., somitic
explants) and followed the induction of bone versus cartilage
markers in these cells (Kempf et al., 2007). We found that exog-
enous Runx2, though capable of inducing the bone marker
osteopontin inmesenchymal progenitor cells, was able to induce
expression of the hypertrophic chondrocyte marker, collagen X,
only in a chondrocytic milieu (Kempf et al., 2007). These findingslopmental Cell 22, 927–939, May 15, 2012 ª2012 Elsevier Inc. 927
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necessary for Runx2 to activate collagen X gene expression. In
the present work, we identify members of the FoxA transcription
factor family as crucial chondrogenic transcription factors that
work in collaboration with Runx and MEF2 factors to drive
expression of collagen X and other hypertrophic chondrocyte
markers.
RESULTS
Both a Chondrogenic Environment and the Presence
of Upstream Enhancer Sequences Are Necessary
for Induction of a Collagen X Reporter by Runx2,
Smad1, and MEF2C
The regulatory regions that drive the expression of human,
mouse, and avian collagen X have been analyzed by a number
of groups (reviewed in Gebhard et al., 2004). These studies
have established that both positive and negative regulatory
regions, which lie upstream of the collagen X gene, play an
important role in the expression of a transgene in either trans-
fected chondrocytes or in transgenic mice. The avian collagen
X enhancer contains a 4.2 kb sequence (termed the ABC
enhancer) located upstream of the coding region that can drive
hypertrophic chondrocyte-specific gene expression, both
in vitro (Lu Valle et al., 1993) and in vivo (Campbell et al., 2004).
Within the ABC enhancer, a 642 bp subfragment (termed the
b2 enhancer) is capable of driving BMP-dependent activation
of the collagen X proximal promoter in hypertrophic chondro-
cytes in vitro (Volk et al., 1998). Therefore, we have employed
the b2 enhancer region appended to a minimal 230 bp sequence
of the proximal collagen X promoter in a luciferase reporter
(b2-230-Luc) to study collagen X regulation in different cellular
environments. Cotransfection with Runx2, Smad1, and MEF2C
expression vehicles robustly activates this reporter in chondro-
cytes but not in fibroblasts (Figure 1A). As Runx2, Smad1, and
MEF2 are competent transcriptional activators in either cell
type (Kempf et al., 2007; data not shown), this result suggests
that either chondrocytes contain an activity that is absent from
fibroblasts, which allows exogenous Runx2, Smad1, and
MEF2C to induce expression of a collagen X-luciferase reporter
only in the former cell type, or that fibroblasts contain an inhibitor
of collagen X expression.
Four Distinct Oligos within the b2 Enhancer Contain
Binding Sites for DNA Binding Activities that Are
Enriched in Chondrocytes
To identify a putative ‘‘chondrocyte-specific’’ transcription
factor(s) that is required for collagen X expression, we performed
an electrophoretic mobility shift assay (EMSA) with 40 bp oligos
that were tiled across either the entire b2 enhancer or the prox-
imal promoter region in 20 bp overlaps. These oligos were
incubated with nuclear extracts made from either chicken
embryonic upper sternal chondrocytes (C) or chicken embryonic
fibroblasts (F). By performing this analysis, we identified four
oligos that interacted with DNA binding factors that were either
enriched or present only in chondrocyte nuclear extracts. These
four sequences (labeled oligos 1–4 in Figure 1B) were distributed
within the b2 enhancer and flanked binding sites for both Runx2
and MEF2C (Figure S1A available online). These sequences928 Developmental Cell 22, 927–939, May 15, 2012 ª2012 Elsevier Inbound two classes of protein complexes with distinct electro-
phoretic mobilities: a fast mobility complex (FMC) and a slow
mobility complex (SMC). Though the FMC bound equally well
to all four oligos in the presence of competitor dIdC or dGdC,
the SMC bound these same oligos only in the presence of
dGdC and was competed off the oligos by dIdC (Figure 1B).
Additionally, the SMC bound to multiple additional sites on the
b2 enhancer that were not bound by the FMC (Figure S1B).
Mutation of FMC/SMC Binding Sites Cripples b2
Enhancer Activity in Chondrocytes
To identify the binding sites for the FMC and SMC, we per-
formed a 5 bp scanning mutagenesis, which interconverted Gs
with Ts and As with Cs, on oligos 1–4 (shown for oligo 1 in
Figures S1C and S1D). This analysis mapped the sequences
within each oligo that are required for interaction with the
chondrocyte-specific complexes and revealed that both FMC
and SMC bound to a common motif, ACAAANA (outlined in
Figure 1C). Not surprisingly, mutation of the ACAAA core motif
eliminated both the FMC and SMC chondrocyte-specific gel
shifts (Figure 1D). To determine whether loss of FMC/SMC
binding sites would affect expression of a collagen X transgene,
we built thesemutations into the luciferase reporter driven by the
b2 enhancer sequences (b2-230-Luc). We mutated the ACAAA
sequence in either both sites 1 and 2, both sites 3 and 4, or
a combination of all four binding sites (Figure 1E). We observed
an additive decrease in b2 enhancer activity of the collagen X
reporter as we mutated more sites, with a maximal 95%
decrease when we mutated all four FMC/SMC binding sites
(Figure 1E).
The Slow Mobility Complex Contains Sox5
Mutagenic analyses revealed that Runx2 andMEF2 binding sites
in the b2 collagen X enhancer work in combination with binding
sites for the FMC/SMC complexes to promote maximal activity
of this enhancer in chondrocytes (Drissi et al., 2003; Figure S2).
Thus, we focused our attention on discovering the identity of
the SMC and FMC transcription factors. Whereas the FMC
bound only to oligos 1–4, the SMC bound to several other sites
in the b2 enhancer (Figure S1B). A common feature shared
between these other SMC binding sites and the core motif of
the FMC/SMC binding site (ACAAANA) is that they both contain
A- and T-rich regions. Interestingly, the Sox family of transcrip-
tion factors are similarly known to bind to runs of As and Ts
(Wegner, 2005). Additionally, like the SMC factor, interaction
of Sox transcription factors with their cognate binding site is
inhibited by competitor dIdC but not by dGdC (Wegner, 2005).
In light of these similarities between members of the Sox family
and the SMC factor, we investigated whether in vitro translated
Sox5 or Sox9 would bind to oligos 1–4 and whether antibodies
that recognize different Sox family members would ‘‘double
shift’’ the SMC. We found that both in-vitro-translated Sox5
andSox9 could bind to these oligos as assayed by EMSA (shown
for oligo 1 in Figure 2A). Of all the antibodies employed (i.e.,
against Sox5, Sox6, Sox9, and Sox13), we found that antibodies
that recognized two distinct regions of Sox5 could specifically
double shift the SMC gel shift on oligos 1–4 (shown for oligo 1
in Figure 2B). These findings indicate that Sox 5 is a component
of the slow mobility complex.c.
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Figure 1. Characterization of Chondrocyte-
Specific Transcription Factor Binding Sites
within the Chicken Collagen X Enhancer
(b2) that Are Critical for Promoter Activity
(A) Either upper sternal chondrocytes or fibro-
blasts isolated from chicken embryos were co-
transfected with a collagen X luciferase reporter
(b2-230-Luc) plus Smad1/Runx2/MEF2C expres-
sion vectors as indicated. The reporter is com-
prised of the b2 collagen X enhancer appended to
a 230 bp proximal promoter region driving the
expression of the Renilla Luciferase gene. In both
this and subsequent experiments, Renilla Lucif-
erase Units were normalized to the expression of
a cotransfected SV40-Firefly Luciferase vehicle.
Significance was calculated using Student’s
t test, * denotes statistical significance at p% 0.01.
Error bars indicate standard error of the mean
(SEM), where n = 3.
(B) Electrophoretic mobility shift assay (EMSA)
was performed using nuclear extracts derived
from either chondrocytes [C] or fibroblasts [F]. The
proteins were incubated with selected sequences
(oligos 1–4) within the b2 enhancer in the presence
of either dIdC or dGdC as nonspecific competi-
tors. Two chondrocyte-specific complexes: a slow
mobility complex (SMC) and a fast mobility
complex (FMC) are shown by arrowheads.
(C) The nucleotides critical for the interaction of the
chondrocyte-specific complexes (SMC/FMC) with
the DNA are displayed in blue. The common core
motif ACAAA, present in each oligo, is outlined in
the red box.
(D) EMSA was performed using chondrocyte
nuclear extracts incubated with either wild-type
(W) oligos 1–4 or those containing mutations (M) in
the ACAAA sequence, in the presence of dGdC or
dIdC as indicated.
(E) Schematic of wild-type andmutant b2-230-Luc
reporter constructs with mutations of the ACAAA
sequence located in oligos 1–4 as indicated (‘‘X’’
represents site of mutation). Activity of these
constructs in transfected chondrocytes is shown
in either the absence or presence of cotransfected
Smad1 and Runx2 expression vehicles plus BMP2
(S/R/B). Significance was calculated using
Student’s t test, * denotes statistical significance
at p % 0.02. Error bars indicate standard error of
the mean (SEM), where n = 3.
See also Figures S1 and S2.
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FoxA Factors Induce Chondrocyte HypertrophyTransfection of Sox Factors Decreases the Activity
of the Collagen X Enhancer in Chondrocytes
and Fails to Activate This Enhancer in Fibroblasts
As the SMC/FMC binding sites are required for maximal b2
enhancer activity, we explored whether ectopic expression of
the SMC factor, Sox5, would augment the activity of the collagen
X-reporter driven by this enhancer (b2-230-Luc). We found that
cotransfection of Runx2 and Smad1 with any of the chondro-
genic Sox family members (i.e., Sox5, Sox6, or Sox9) failed to
activate this reporter in fibroblasts and that these same Sox
factors dampened the induction of the collagen X-reporter by
Runx2 and Smad1 in chondrocytes (Figure 2C). Together, these
results suggest that the decrease of collagen X enhancer activity
followingmutation of the combined SMC/FMCbinding sites (Fig-Deveure 1E) are unlikely to be due to a loss of interaction with Sox5
(which is present in the SMC) but rather may reflect the loss of
interaction of the FMC with the collagen X enhancer. As Sox5
is present within the nuclei of chondrocytes that express
collagen X (Figure 2D), it is possible that Sox5 serves to dampen
the expression of collagen X by competing with the FMC factor
for a common binding site.
FoxA2 Is Present in the Fast Mobility Complex
Sequence comparison of the FMCbinding sites revealed that the
ACAAANA core motif of the FMC site includes a consensus Fox
(Forkhead) binding site (see Figure 1C). Prior in situ hybridization
and immunohistochemistry studies in mice embryos have
indicated that FoxA2 and FoxA3 are expressed in developinglopmental Cell 22, 927–939, May 15, 2012 ª2012 Elsevier Inc. 929
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Figure 2. The Slow Mobility Complex Contains
Sox 5
(A) EMSA using in vitro-translated Sox5 and Sox9 incu-
bated with oligo 1.
(B) EMSA using chondrocyte nuclear extracts incubated
with oligo 1 and specific anti-Sox family antibodies as
indicated. Two antibodies made against different domains
of the Sox5 protein (anti-Sox5a and anti-Sox5b) specifi-
cally super-shift the SMC but not the FMC gel shift.
(C) Cotransfection of the b2-230-Collagen X Luciferase
reporter together with Smad1, Runx2, and either Sox5,
Sox6, or Sox9 expression vehicles in either chondrocytes
or fibroblasts. Significance was calculated using
Student’s t test, * denotes statistical significance at p %
0.05. Error bars indicate standard error of the mean (SEM),
where n = 3.
(D) Immunostaining for Sox5 (green) or Collagen X (red) is
displayed in either chondrocytes or fibroblasts. DAPI
staining of DNA is shown in blue.
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FoxA Factors Induce Chondrocyte Hypertrophycartilages (Besnard et al., 2004; Hiemisch et al., 1997;Monaghan
et al., 1993). Thus, we investigated if FoxA family members could
bind to the FMC binding sites in oligos 1–4 and whether anti-
bodies against different Fox family members would ‘‘recognize’’
the FMC. Whereas mice have three FoxA family members (A1,
A2, and A3), browsing the chicken genome revealed that this
genome encodes only FoxA1 and FoxA2. Either in-vitro-trans-
lated FoxA1 or FoxA2 could bind to oligos 1–4 by EMSA (Fig-
ure 3A), and mutation of the ACAAA sequence within each oligo
abrogated the interaction with FoxA2 (Figure 3D). Most impor-
tantly, an antibody that recognizes in-vitro-translated chicken
FoxA2 could also specifically block formation of the FMC gel
shift in chondrocyte nuclear extracts incubated with oligos 1–4
(Figure 3B). In contrast, anti-FoxA1 failed to affect the FMC gel
shift (Figure 3B).
Exogenous FoxA2 Can Activate Expression
of the Collagen X Reporter in Both Chondrocytes
and Fibroblasts
As all four FMC binding sites are required for maximal b2
enhancer activity, we investigated whether ectopic expression
of the FMC factor, FoxA2, would augment the activity of the
full-length collagen X enhancer/promoter (i.e., ABC-230-Luc).
In striking contrast to Runx2/Smad1 overexpression, which
failed to stimulate expression of the collagen X reporter in fibro-930 Developmental Cell 22, 927–939, May 15, 2012 ª2012 Elsevier Inc.blasts, cotransfection of either FoxA1 or FoxA2
robustly activated expression of this reporter
to approximately equivalent levels (in either the
absence or presence of exogenous Runx2/
Smad1) in both transfected upper sternal chon-
drocytes and fibroblasts (Figure 3C). Mutation
of the ACAAA sequence in the various FMC
binding sites of the b2 enhancer both blocked
interaction of the DNA with FoxA2 (Figure 3D)
and led to loss of induction of b2 enhancer
activity by cotransfected FoxA2 (Figure 3E).
The combined loss of all four binding sites
showed the most dramatic decrease of
enhancer activity (Figure 3E). Together, thesefindings indicate that FoxA2 is a component of the chondro-
cyte-specific FMC and that exogenous FoxA2 can activate
expression of the collagen X reporter in both chondrocytes and
fibroblasts.
Chondrogenic Signals Induce the Expression
of FoxA Factors
To determine whether chondrogenic cues induce the expression
of FoxA family members, we assayed their expression during
chondrogenesis in high-density micromass cultures of chicken
limb bud mesenchymal cells. The expression of both FoxA1
and FoxA2 was robustly induced during chondrogenesis of
these cells, slightly trailing that of Runx2 and roughly paralleling
that of VEGF, collagen X, and MMP13 (Figure 4A). As the FMC
factor is present in nuclear extracts made from chicken sternal
chondrocytes and absent from those made from chicken
embryo fibroblasts, we also evaluated the relative expression
of FoxA1 and FoxA2 in these cell types. We found that upper
sternal chondrocytes, but not fibroblasts, express both FoxA1
and FoxA2 as assayed by RT-qPCR (Figure 4B). Interestingly,
we noted that MEF2C is also induced during chondrogenic
differentiation of limb bud cells and is specifically expressed in
chondrocytes but not in fibroblasts (Figures 4A and 4B).
However, whereas FoxA1/A2 could induce expression of the
collagen X luciferase reporter in both chondrocytes and
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Figure 3. The Fast Mobility Complex Con-
tains FoxA2
(A) EMSA using in vitro-translated FoxA1 and
FoxA2 incubated with oligos 1–4.
(B) EMSA using chondrocyte (C) or fibroblast (F)
nuclear extracts (NE) or in vitro- translated FoxA2
(IVT A2) and incubated with oligos 1–4 in the
presence or absence of either anti-FoxA1 or
anti-FoxA2 antibodies as indicated.
(C) Cotransfection of the ABC-230-Collagen X
Luciferase reporter together with Smad1, Runx2
and either FoxA1 or FoxA2 as indicated, in either
chondrocytes or fibroblasts. Significance was
calculated using Student’s t test, there is not a
significant statistical difference (p R 0.05)
between the luciferase activities of the collagen X
luciferase reporter cotransfected with either
FoxA1 or FoxA2 in chondrocytes versus in fibro-
blasts. Error bars indicate standard error of the
mean (SEM) where n = 3.
(D) EMSA of in vitro-translated FoxA2 with either
wild-type (W) oligos 1–4 or those containing
mutations (M) in the ACAAA sequence.
(E) Schematic of wild-type andmutant b2-230-Luc
reporter constructs with mutations of the ACAAA
sequence located in oligos 1–4 as indicated (‘‘X’’
represents the site of mutation). Activity of
these constructs in transfected chondrocytes
is shown in either the absence or presence of a
cotransfected FoxA2 expression vehicle. Signifi-
cance was calculated using Student’s t test,
* denotes statistical significance at p% 0.01. Error
bars indicate standard error of the mean (SEM)
where n = 3.
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FoxA Factors Induce Chondrocyte Hypertrophyfibroblasts, MEF2C could only induce expression of this reporter
in chondrocytes (Figure 4C), and in this cell type to a much
lower level than did cotransfected FoxA factors. Together, these
findings suggest that FoxA factors, which are present in chon-
drocytes yet absent from fibroblasts, may confer competence
for Runx2, Smad1, and MEF2C to activate expression of the
collagen X luciferase reporter in the former cell type.
Overexpression of FoxA2 Increases the Expression of
Endogenous Markers of Chondrocyte Hypertrophy, and
Knockdown of FoxA2 Delays Chondrocyte Hypertrophy
Because forced expression of FoxA2 could boost the expression
of the collagen X luciferase reporter in chondrocytes, we investi-
gated whether exogenous FoxA2 would similarly increase theDevelopmental Cell 22, 927–expression of endogenous markers of
chondrocyte hypertrophy. We infected
chicken sternal chondrocytes with an
avian retrovirus encoding either GFP
(RCAS-GFP) or FoxA2 (RCAS-FoxA2).
Because BMP signals are known to
induce chondrocyte hypertrophy (Volk
et al., 1998, 2000), we cultured the cells
in BMP2 for increasing periods of time.
Expression of retroviral-encoded FoxA2
specifically increased the expression of
endogenous collagen X up to 3-foldfollowing 8 days culture in BMP2 (Figure 4D). Interestingly,
RCAS-FoxA2 infection strikingly boosted the expression of the
late chondrocyte hypertrophic marker MMP13 up to 60-fold,
and in this case, robust induction was observed in either the
absence or presence of exogenous BMP2 (Figure 4D). The fact
that viral FoxA2-induced expression of collagen X was delayed
relative to that of MMP13 suggests that induction of collagen X
by FoxA2 may require other factors (i.e., Runx2 and MEF2C),
whose expression/activity is rate-limiting in upper sternal chon-
drocytes until after 8 days culture in BMP2. Consistent with
this notion, ectopic FoxA2 only boosted the expression of
endogenous collagen X in chondrocytes and not in other cell
types (data not shown). In contrast, FoxA2-mediated induction
of MMP13 was observed in both chondrocytes and in the939, May 15, 2012 ª2012 Elsevier Inc. 931
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Figure 4. Overexpression or Knockdown of FoxA2 Increases or Decreases Expression, Respectively, of Several Hypertrophic Chondrocyte
Markers
(A) Limb bud mesenchymal cells were cultured under high density micromass conditions for the indicated number of days. Gene expression was assayed by
RT-qPCR. In both this and subsequent experiments, transcript levels were normalized to GAPDH levels. Significance was calculated using Student’s t test,
* denotes statistical significance at p% 0.05 when gene expression in high-density micromass cultures at various time points is compared with gene expression
at the initial time of plating. Error bars indicate standard error of the mean (SEM), where n = 3.
(B) FoxA1, FoxA2, and MEF2C are expressed in chondrocytes (C) but not in fibroblasts (F) as assayed by RT-qPCR. Significance was calculated using Student’s
t test, * denotes statistical significance at p % 0.01 when gene expression in chondrocyte cultures is compared with gene expression in fibroblast cultures.
Error bars indicate standard error of the mean (SEM), where n = 3.
(C) Either chondrocytes or fibroblasts were cotransfected with the b2-230-Luc reporter in either the absence or presence of exogenous FoxA2 or MEF2C,
as indicated. Significance was calculated using Student’s t test, * denotes statistical significance at p % 0.05 when luciferase activites from either FoxA2
or MEF2C cotransfected cells are compared to luciferase activities of control vehicle transfected cells. Error bars indicate standard error of the mean (SEM),
where n = 3.
(D) Overexpression of FoxA2 increases expression of several hypertrophic chondrocyte markers. Chondrocytes were infected with an avian retrovirus encoding
either GFP (RCAS-GFP; black bars) or FoxA2 (RCAS-mFoxA2; gray bars). Cells were cultured in BMP2 for the indicated number of days and subsequently
gene expression was assayed by quantitative real time PCR. Transcript levels relative to GAPDH are displayed. Significance was calculated using Student’s
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FoxA Factors Induce Chondrocyte Hypertrophyosteoblast line MC3T3 (data not shown). In addition, we noted
that exogenous FoxA2 also induced the expression of VEGF
up to 6.3-fold, alkaline phosphatase up to 14.7-fold (Figure 4D),
and boosted collagen II expression (2.5-fold) but only at early
times of culture (data not shown). Conversely, infection of chon-
drocytes with an avian retrovirus programmed to express
shFoxA2 (RCAS-shFoxA2) significantly decreased BMP2-medi-
ated induction of endogenous FoxA2, MMP13, collagen X,
VEGF, and alkaline phosphatase but had little effect on collagen
II expression (Figure 4E and data not shown). The loss of
collagen X and other hypertrophic markers following the knock-
down of FoxA2 in chondrocytes suggests that FoxA2 is neces-
sary (directly or indirectly) to promote maximal expression of
these genes in hypertrophic chondrocytes.
FoxA2 and FoxA3 Exhibit Distinct Chondrocyte-Specific
Expression Patterns
Prior in situ hybridization and immunohistochemistry studies in
mice embryos have indicated that FoxA2 and FoxA3 are ex-
pressed in the developing skeleton in vivo (Besnard et al.,
2004; Hiemisch et al., 1997; Monaghan et al., 1993). To further
characterize FoxA3 expression in the developing skeleton, we
genetically labeled all descendants of cells that have expressed
FoxA3. We used a transgenic mouse line (FoxA3-Cre) containing
a 170 kb yeast artificial chromosome that encompasses the
entire FoxA3 locus, which faithfully reproduces the expression
of the endogenous gene, and drives the expression of Cre
DNA recombinase in vivo (Lee et al., 2005). Mating of FoxA3-
Cre males with ROSA26 reporter females, which contain a
Cre-inducible LacZ locus (Soriano, 1999), results in beta-galac-
tosidase expression in all cells (and their descendents) that
express FoxA3. In FoxA3-Cre; ROSA26 newborn mice, X-gal
staining, which detects beta-galactosidase activity, was
apparent in all cartilaginous elements of the skeleton but was
absent from bone tissue (Figure 5A, panels a–c). Histological
analysis of newborn tibias revealed the presence of X-gal posi-
tive cells in all three layers of the growth plate: immature round
cells, columnar flat chondrocytes, and hypertrophic chondro-
cytes (Figure 5B, panels 5–7). In contrast, no labeled cells were
detected in trabecular bone (Figure 5B, panel 8), and staining
was not observed in control ROSA26 reporter mice alone
(Figure 5B, panels 1–4). These results indicate that FoxA3 is
expressed in immature chondrocytes and possibly in their
descendants (see Discussion).
For a detailed analysis of FoxA2 expression in the developing
skeleton, we employed a tamoxifen-inducible Cre driver
(CreERT2) knocked into the 30 UTR of the FoxA2 gene behind
an IRES sequence (Park et al., 2008). FoxA2-CreERT2 males
were crossed with ROSA26 females, and a single IP injection
of tamoxifen was administered to the pregnant females at either
7 or 14 dpc; the embryos were harvested after either 2, 4, ort test, * denotes statistical significance at p% 0.05when gene expression in chond
in chondrocyte cultures infected with RCAS-GFP. Error bars indicate standard e
(E) Knockdown of FoxA2 decreases expression of several hypertrophic chondro
either a scrambled shRNA (RCAS-sh-nonGFP; black bars) or shRNA targeting Fox
number of days and subsequently gene expression was assayed by quantitative
was calculated using Student’s t test, * denotes statistical significance at p% 0.05
is compared with gene expression in chondrocyte cultures infected with RCAS-s
Deve11 days following tamoxifen administration. In the axial skeleton
(i.e., vertebrae) of embryos administered tamoxifen at 7 dpc and
harvested 11 days later, X-gal-positive cells were present in both
the intervertebral discs as well as throughout the vertebral
bodies (Figure 5C, top panels 4–6). In contrast, in the axial
skeleton of embryos that were administered tamoxifen at 14
dpc and harvested 2 or 4 days later, only the hypertrophic
chondrocytes located in the center of the vertebral bodies
were X-gal positive (Figure 5C, top panel 3), whereas cells in
either the nucleus pulposus or less-mature chondrocytes ex-
hibited no staining (Figure 5C, top panels 1 and 2). Together,
these findings suggest that FoxA2 is initially expressed in a pop-
ulation of progenitor cells that gives rise to various structures of
the vertebral column, whereas at later times, expression of this
gene is restricted to hypertrophic chondrocytes.
Sternum development is delayed in comparison to vertebral
column development. In the sternum, X-gal staining was only
detectable in the hypertrophic chondrocytes of mice embryos
injectedwith tamoxifen at 14 dpc and harvested 4 days later (Fig-
ure 5C, middle panels 1–4). In the appendicular skeleton of mice
embryos injected with tamoxifen at 14 dpc, X-gal staining was
also present in hypertrophic chondrocytes of the growth plate
and in a few sparse cells in the prehypertrophic region but was
absent from either perichondrial cells or immature chondrocytes
(Figure 5C, bottom panels 1–3). Interestingly, in embryos in-
jected with tamoxifen at 7 dpc and harvested 11 days later, no
cells were labeled in either the sternum (Figure 5C, large middle
right panel) or the appendicular skeleton (Figure 5C, large
bottom right panel). Thus, in contrast to the axial skeleton,
FoxA2 expression in both the sternum and appendicular skel-
eton is apparently restricted to hypertrophic chondrocytes.
Chondrocyte-Specific Knockout of FoxA2 and FoxA3 in
Mice Results in Postnatal Dwarfism, Loss of Collagen X
Expression, and Decreased Expression of Other
Chondrocyte Hypertrophy Markers
Mice homozygous for a FoxA2 null allele die at E10–E11 because
of severe defects in the node, notochord, neural tube, and gut
tube (Ang and Rossant, 1994; Weinstein et al., 1994), precluding
an analysis of the role of FoxA2 at later stages of development.
Thus, to evaluate the role of FoxA2 in cartilage development,
we conditionally deleted FoxA2 in developing chondrocytes
using a mouse line that expresses Cre recombinase controlled
by the collagen2a1 promoter (Col2-Cre; Long et al., 2001) plus
engineered alleles of FoxA2 that contain loxP sites (Sund et al.,
2000). To test for potential redundancy between different FoxA
family members, we conditionally deleted FoxA2 alone or in
a FoxA3/ background, since FoxA3 null mice are viable and
display no skeletal abnormalities (Kaestner et al., 1998; Shen
et al., 2001). Both two-allele deletion mutant mice (Col2-Cre;
FoxA2flox/flox) (aka, two null alleles; 2NA) and four-allele deletionrocyte cultures infectedwith RCAS-mFoxA2 is comparedwith gene expression
rror of the mean (SEM), where n = 3.
cyte markers. Chondrocytes were infected with an avian retrovirus encoding
A2 (RCAS-sh-cFoxA2; gray bars). Cells were cultured in BMP2 for the indicated
real time PCR. Transcript levels relative to GAPDH are displayed. Significance
when gene expression in chondrocyte cultures infected with RCAS-sh-cFoxA2
h-nonGFP. Error bars indicate standard error of the mean (SEM), where n = 3.
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Figure 5. Chondrocyte-Specific Knockout of
FoxA2 and Deletion of FoxA3 in Mice Results in
Delayed Hypertrophy and Postnatal Dwarfism
(A) Whole mount X-gal staining of the skeleton of newborn
FoxA3-Cre; ROSA26 mice as compared with control
ROSA26 littermates (Aa–Ac).
(B) X-gal/ Fast Red staining of tibial sections of newborn
FoxA3-Cre; ROSA26 mice (panels 5–8) compared with
control littermates (panels 1–4).
(C) Hematoxylin and eosin (H&E) and X-gal staining on
sections of either vertebrae, second sternebra, or forelimb
digit from FoxA2-CreERT2; ROSA26 mice that were
administered tamoxifen by intraperitoneal (IP) injection at
either 7 or 14 dpc and harvested at the various times as
indicated.
(D) Alcian Blue/Alizarin Red skeletal preparations of either
sternum, vertebral column, tail, or forelimb from E19.5
Col2-Cre; FoxA2flox/flox (2 null alleles; 2NA) mice embryos,
Col2-Cre; FoxA2flox/flox; FoxA3/ (4 null alleles; 4NA)
mice embryos or their control littermates.
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alleles; 4NA) were recovered with the expected Mendelian ratio,
but they died at birth or in the immediate postnatal period, and
very few mice survived postweaning time. Conditional FoxA2
null mice were readily recognizable by their misshaped ‘‘curly’’
tails (Figures 5D and 7B). Staining of cartilage and mineralized
bone using Alcian blue and Alizarin red, respectively, revealed
multiple skeletal defects in both axial and appendicular skele-
tons of E19.5 embryos lacking either FoxA2 or both FoxA2
and FoxA3 in their developing cartilages (Figure 5D). Whereas
loss of FoxA2 alone led to a slight delay in cartilage calcification,
loss of both FoxA2 and FoxA3 led to a profound loss of
mineralization in both sternebrae and vertebrae (Figure 5D). A
small subset of mutant mice exhibited kyphosis because of mis-
shaped or fused thoracic vertebrae (Figure 5D). Moreover, in all
mutants, loss of FoxA2/3 led to an extreme fusion of caudal
vertebrae, mostly toward the distal end of the tail (Figure 5D).
This was also apparent, but less extreme, in mice lacking only
FoxA2 in their chondrocytes (Figure 5D). Interestingly, cartilage
calcification in the appendicular skeleton was also decreased934 Developmental Cell 22, 927–939, May 15, 2012 ª2012 Elsevier Inc.but less affected by loss of FoxA2/3 than the
axial cartilages (Figure 5D).
In light of the skeletal abnormalities observed
in the Col2-Cre; FoxA2flox/flox; FoxA3/ mice,
we further characterized cartilage hypertrophy
in these animals. Histological analysis showed
only residual hypertrophic chondrocytes in
the sterna of E19.5 mutant mice. Moreover,
these small islands of hypertrophic cells were
misaligned, indicating that chondrocyte hyper-
trophy was not properly coordinated in the
progeny of the two fused sternal bars (Figure 6A,
panels a and b). To further characterize this
population of hypertrophic cells, we assayed
both alkaline phosphatase activity and matrix
mineralization by von Kossa staining. Interest-
ingly, though the residual hypertrophic cells in
the sternebrae of E19.5 Col2-Cre; FoxA2flox/flox;FoxA3/ embryos display an enlargement in cell volume (Fig-
ure 6A, panels a and b), they lack significant alkaline phospha-
tase activity (Figures 6B and 6D, panels a and b) and little if
any matrix mineralization (Figure 6C, panels a and b). Similarly,
the cephalic and caudal vertebraewere severelymisshapen, dis-
played a deficit of hypertrophic cells, and the nucleus pulposus
was frequently absent between vertebrae primordia in the tails
of these mutant embryos (Figure 6A, panels c–f). Alkaline phos-
phatase activity was present in the periosteal cells lining the
vertebrae of both mutant and control mice but was significantly
diminished in the vertebral bodies of mutant mice (Figures 6B
and 6D, panels c–f) as was matrix mineralization, as assayed
by von Kossa staining (Figure 6C, panels c–f). In contrast to
the axial cartilage, which displayed gross maturation defects,
the appendicular cartilage of E19.5 mutant mice was relatively
normal in embryos lacking FoxA2/3 in their chondrocytes but
displayed less trabeculae, less mineralization, and attenuated
expression of alkaline phosphatase relative to their control litter
mates (Figures 6A–6D, panels g and h). The delay in cartilage
degradation and bone invasion in the appendicular cartilage of
ctrl         4NA ctrl         4NA ctrl         4NA 
H&E  Alk. Phosphatase    von Kossa  
a b a b a b 
c d c d c d 
e f e f e f 
g h g h g h 
i j i j i j 
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c d 
g h 
i j 
e 
f1 
f2 
A B C D Figure 6. Chondrocyte-Specific Knockout of
FoxA2 and Deletion of FoxA3 in Mice Results in
Delayed Hypertrophy, Loss of Alkaline Phospha-
tase Activity, and Delayed Mineralization
(A–C) Sections of either E19.5 sternebrae (a, b), thoracic
vertebrae (c, d), caudal vertebrae (e, f), femurs (g, h), or
E16.5 femurs (i, j) taken from either control or Col2-Cre;
FoxA2flox/flox; FoxA3/ (4NA) embryos were stained with
either H&E (A), for alkaline phosphatase activity (B), or with
von Kossa stain (C).
See also Figures S2 and S3.
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embryos (Figures 6A–6D, panels i and j).
To further characterize cartilage maturation in embryos lack-
ing FoxA2 and FoxA3 in their chondrocytes, we assayed the
expression of collagen II, collagen X, and MMP13, which are ex-
pressed in either immature, early hypertrophic, or late hypertro-
phic chondrocytes, respectively. Although expression of
collagen II was not significantly affected in the tibial growth
plates of E19.5 Col2-Cre; FoxA2flox/flox; FoxA3/ embryos,
expression of collagen X was severely decreased and that of
MMP13 was markedly attenuated in these embryos (Figure 7A).
A small fraction of Col2-Cre; FoxA2flox/flox; FoxA3/ mice (4NA)
survived postnatally. Skeletal staining of these 2-week-old 4NA
mice indicated that they displayed dwarfism, had smaller rib ca-
ges, frequently lacked a xiphoid process, had fused vertebrae in
their tail, and had long bones that were relatively short (Fig-
ure 7B). Consistent with the smaller size of these mutant animals
relative to their normal littermates at 2 weeks of age, the tibialDevelopmental Cell 22growth plates in the Col2-Cre; FoxA2flox/flox;
FoxA3/ mice were smaller, with a specific
deficiency of cells in the hypertrophic zone but
not in the proliferating zone (Figure 7C). These
results are supported by in situ hybridization
analysis, which revealed that expression of
both collagen X and MMP13 were significantly
diminished in the tibial growth plates of
2-week-old Col2-Cre; FoxA2flox/flox; FoxA3/
mice relative to their control littermates (Fig-
ure 7D). Together, these findings indicate that
both FoxA2 and FoxA3 are necessary to pro-
mote high-level expression of several hypertro-
phic chondrocyte markers in the growth plate,
including collagen X, alkaline phosphatase,
and MMP13.
DISCUSSION
FoxA Factors Are Required for
Expression of Both Collagen X and Other
Hypertrophic Chondrocyte Markers
In prior work, we found that exogenous Runx2
can induce the expression of chondrocyte
hypertrophy markers, such as collagen X and
Ihh, only in chondrogenic cells (Kempf et al.,
2007), suggesting that this cell type may specif-
ically express a competence factor that allowsRunx2 to activate expression of chondrocyte hypertrophy
markers. To identify this factor, we performed EMSA with oligos
tiled across the minimal chicken collagen X enhancer and
thereby identified two chondrocyte-specific transcription
factors, Sox5 and FoxA2, which bind to essential sequences
that are reiterated within this enhancer. In this work, we demon-
strate that FoxA factors are induced during chondrogenesis, that
ectopic expression of FoxA factors can boost the expression of
a collagen X-reporter in both chondrocytes and fibroblasts, and
that expression of collagen X,MMP13, and alkaline phosphatase
are markedly attenuated in mice lacking FoxA2 and FoxA3 in
their cartilage.
Interestingly, we found that the axial and appendicular carti-
lage elements displayed differential sensitivities to the loss of
FoxA2 and FoxA3. Although chondrocyte hypertrophy, mineral-
ization, and alkaline phosphatase activity were nearly extin-
guished in sternebrae and tail vertebrae of E19.5 Col2-Cre;
FoxA2flox/flox; FoxA3/ embryos, these markers of chondrocyte, 927–939, May 15, 2012 ª2012 Elsevier Inc. 935
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Figure 7. Chondrocyte-Specific Knockout
of FoxA2 and Deletion of FoxA3 in Mice
Results in Loss of Hypertrophic Chondro-
cyte Gene Expression in the Growth Plate
(A) In situ hybridization analysis of tibial growth
plates for the indicated genes is displayed for
either E19.5 Col2-Cre; FoxA2flox/flox; FoxA3/
(4NA) embryos or their control littermates.
(B) Alcian Blue/Alizarin Red skeletal preparations
of 2-week-old Col2-Cre; FoxA2flox/flox; FoxA3/
(4NA) mice or their control littermates.
(C) H&E staining of tibial epiphysis of either
2-week-old Col2-Cre; FoxA2flox/flox; FoxA3/
(4NA) mice or control littermates. Quantification of
the thickness of either the proliferative zone (PZ) or
the hypertrophic zone (HZ) in the tibial growth
plates is displayed. Significance was calculated
using Student’s t test, * denotes statistical signif-
icance at p % 0.001 when tibial growth plate
zones from 2-week-old 4NA mutant mice are
compared to the tibial growth plate zones from
control animals. Error bars indicate standard error
of the mean (SEM) where n = 6.
(D) In situ hybridization analysis of tibial growth
plates for the indicated genes is displayed for
either 2-week-old Col2-Cre; FoxA2flox/flox;
FoxA3/ (4NA) mice or their control littermates.
See also Figures S4 and S5.
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appendicular skeletal elements. It is not clear why axial and
appendicular cartilage elements display this differential sensi-
tivity to the loss of FoxA2/3; however, this finding suggests
that there is differential expression of a factor(s) that compen-
sates for the loss of FoxA2/3 in axial versus appendicular
cartilage. It will be interesting to determine whether FoxA1,
which is expressed along with FoxA2/3 in metatarsal explants
(Figure S3), is differentially expressed in axial versus appendic-
ular cartilage to allow hypertrophic chondrocyte gene expres-
sion in the absence of FoxA2/3 in these latter skeletal elements.
In addition, we also noted that not all markers of hypertrophic
chondrocyte differentiation are equally affected by the loss of
FoxA2 and FoxA3. Whereas the number of hypertrophic cells
in the growth plates of Col2-Cre; FoxA2flox/flox; FoxA3/ mice
were diminished relative to control littermates, the hypertrophic
chondrocytes within these growth plates clearly underwent an
increase in cell size. In contrast, collagen X expression in the
hypertrophic chondrocytes was nearly extinguished in Col2-
Cre; FoxA2flox/flox; FoxA3/mice. In addition, whereas chondro-
cyte hypertrophy was markedly blunted in the sternebrae of
these animals, residual pockets of large hypertrophic chondro-
cytes that lacked significant alkaline phosphatase activity and936 Developmental Cell 22, 927–939, May 15, 2012 ª2012 Elsevier Inc.failed to mineralize could be observed.
Thus, the hypertrophic growth of chon-
drocytes can apparently be uncoupled
from the expression of hypertrophic
chondrocyte markers, such as collagen
X and alkaline phosphatase.
Some of the features of the Col2-Cre;
FoxA2flox/flox; FoxA3/ mice are re-
produced in two mouse models ofhypophosphatasia characterized by knockout of the tissue-
non-specific isoenzyme of alkaline phosphatase (TNSALP)
(Fedde et al., 1999). Mice deficient for this enzyme are normal
during the first week of age, but develop osteopenia andmultiple
fractures shortly thereafter, when they exhibit severe growth
retardation characterized by shortened limbs with delayed
ossification centers and a markedly reduced hypertrophic
zone. These characteristics are similar to the phenotype of the
2-week-old Col2-Cre; FoxA2flox/flox; FoxA3/ mice, consistent
with the depressed alkaline phosphatase activity in the growth
plate of these animals.
Chondrogenic Cues Induce the Expression of FoxA
Factors in Mesenchymal Cells
FoxA1/2 and FoxA3 expression are induced in primary cultures
of either chicken or murine limb budmesenchymal cells, respec-
tively, when such cells are induced to differentiate into chondro-
cytes (this study and Hoffman et al., 2006). The induction of FoxA
family members during in vitro chondrogenesis of limb bud
mesenchymal cells is consistent with in vivo findings that FoxA
family members are specifically expressed in the cartilage
anlagen. FoxA3-Cre; ROSA26 mice exhibit X-gal staining in all
cartilaginous elements of the skeleton but not in their bone
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FoxA Factors Induce Chondrocyte Hypertrophytissue. In addition, FoxA3-Cre; ROSA26 mice display X-gal
staining in all chondrocyte populations, including immature, pre-
hypertrophic, and hypertrophic chondrocytes. However, since
this Cre line is noninducible, we cannot distinguish whether
FoxA3 is only expressed in cartilage progenitor cells (which will
yield descendants that stably express beta-galactosidase after
FoxA3 expression is extinguished) or if FoxA3 continues to be
expressed in immature, prehypertrophic, and hypertrophic
chondrocytes. A pulse of tamoxifen to E7 FoxA2-Cre-ERT2;
ROSA26 embryos gave rise to X-gal positive cells in both the
intervertebral discs as well as throughout the vertebral bodies
but in neither the sternum nor limbs, suggesting that FoxA2 is
initially expressed in a progenitor population that gives rise to
different structures in the vertebral column. In contrast, if the
window of tamoxifen exposure began at E14, only hypertrophic
chondrocytes in both the axial and appendicular skeleton ex-
pressed beta-galactosidase, suggesting that eventually FoxA2
expression is restricted to hypertrophic chondrocytes.
FoxA Factors Work in Competition with Sox Factors
and in Synergy with Runx2/3, MEF2C/D, and Smad1/4
to Drive Expression of Collagen X
In contrast to the immature chondrocyte differentiation program,
which is driven by Sox transcription factors (de Crombrugghe
et al., 2001; Lefebvre, 2002), the hypertrophic chondrocyte
differentiation program is induced by the combined activities of
Runx2/3 (Yoshida et al., 2004), MEF2C/D (Arnold et al., 2007),
and FoxA2/3 (this work; summarized in Figure S4). Whereas
each of these transcription factor families is expressed in other
cells types, the requirement for the combination of these tran-
scription factors to induce collagen X expression renders
expression of this gene specific to hypertrophic chondrocytes.
In addition, we noted that Sox5 (and Sox6 and Sox9) are able
to bind to the same sequences in the chicken collagen X
enhancer as FoxA family members. Although ectopic expression
of FoxA factors markedly boosted the expression of a collagen
X-luciferase reporter in both chondrocytes and fibroblasts,
ectopic expression of either Sox5, Sox6, or Sox9 repressed
induction of this reporter by Runx2/Smad1 in chondrocytes.
These findings suggest that Sox transcription factors, which
are expressed in immature chondrocytes and downregulated
in hypertrophic chondrocytes, may act to compete for FoxA
factor binding to the collagen X enhancer and thereby inhibit
precocious expression of collagen X and/or other hypertrophic
markers in immature chondrocytes. Indeed, others have noted
that mutation of a Sox9 binding site within the murine Col10a1
enhancer is required to repress expression of a transgene driven
by this enhancer in nonhypertrophic chondrocytes (Leung et al.,
2011).
FoxA factors have been termed pioneer DNA binding factors
that are able to bind nucleosomal covered DNA and to disrupt
local chromatin structure (Cirillo et al., 2002). Indeed FoxA
factor-chromatin interaction has been demonstrated to facilitate
binding of other transcription factors, including the androgen,
estrogen, and glucocorticoid receptors to adjacent binding
sites (reviewed in Kaestner, 2010). Thus, it is possible that
FoxA factors may provide competence for expression of
collagen X by promoting the interaction of other transcription
factors, such as Runx2/3 and MEF2C/D with adjacent bindingDevesites in the regulatory region of this gene. Consistent with this
notion, we have found that binding sites for Runx2/3 and
MEF2C/D are flanked by FoxA binding sites in the chicken
collagen X enhancer (summarized in Figure S1A). It will be inter-
esting to determine whether FoxA factors allow accessibility of
the collagen X enhancer to these other families of transcription
factors and/or promote the assembly of an enhancesome-like
structure containing these many classes of transcription factors
on this regulatory region.
A 535 bp enhancer located upstream of the human collagen X
gene was demonstrated to drive expression of a reporter gene
specifically in hypertrophic chondrocytes (Chambers et al.,
2002; Riemer et al., 2002). This enhancer sequence is conserved
upstream of human, mouse, and bovine collagen X genes (Geb-
hard et al., 2004), and a 4.6 kb fragment upstream of the mouse
collagen X gene containing this enhancer can drive hypertrophic
chondrocyte-specific expression of beta-galactosidase in trans-
genic mice (Gebhard et al., 2004). Whereas regions of extensive
sequence similarity to the human collagen X enhancer are also
present upstream of the mouse and bovine collagen X genes,
the chicken collagen X ABC enhancer does not share continuous
blocks of sequence similarity with this sequence (Gebhard et al.,
2004). Interestingly, however, six conserved FoxA binding sites
are present within the conserved region of the human collagen
X enhancer that are also present upstream of the murine and
bovine collagen X genes (Figure S5A; putative FoxA binding sites
outlined in light blue) and flank Runx2 binding sites that are also
conserved in the human, murine, and bovine collagen X
enhancers (Figure S5A; outlined in yellow). Cotransfection of
a luciferase reporter (4.6 kb mcol10-Luc) driven by both the
mouse collagen X enhancer and proximal promoter, together
with either murine FoxA1, FoxA2, or FoxA3, revealed that the
enhancer activity of this regulatory region is significantly boosted
by exogenous FoxA factors (Figures S5B and S5C). In contrast,
expression of a mouse collagen X reporter lacking the upstream
conserved enhancer sequences (1 kb mcol10-Luc) was only
slightly augmented by cotransfected FoxA factors (Figures S5B
and S5C). Thus, the presence of conserved FoxA and Runx2
binding sites in bothmammalian and avian collagen X enhancers
suggests that these transcription factors may directly activate
the expression of collagen X in hypertrophic chondrocytes of
both mammals and birds.
EXPERIMENTAL PROCEDURES
Cell Culture and Luciferase Reporter Assay
Chondrocytes were isolated from the cephalic portion of day 15 chicken
embryo sterna and cultured as previously described (Leboy et al., 1989). Cells
were subsequently plated at 150,000 cells/well into six-well plates and trans-
fected with the indicated expression plasmids using Superfect transfection
reagent (QIAGEN) according to the manufacturer’s protocol. Cells were lysed
48 hr after transfection, and luciferase reporter activity was determined using
the dual-luciferase reporter assay system (Promega). Limb bud mesenchymal
cells were isolated from stage 22-24 chicken embryos and cultured under mi-
cromass conditions of extremely high cell density (Ahrens et al., 1977; Osdoby
and Caplan, 1979) Metatarsals were isolated from 15.5-day postcoitum (dpc)
pregnant female mice and cultured as described (Guo et al., 2006).
EMSA
Nuclear protein extracts were prepared as previously described (Lee et al.,
2004) and in vitro translated FoxA2 protein was obtained using a TNT Quicklopmental Cell 22, 927–939, May 15, 2012 ª2012 Elsevier Inc. 937
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FoxA Factors Induce Chondrocyte HypertrophyCoupled Transcription/Translation System (Promega) according to manufac-
turer’s protocol. The mobility shift assay was performed as previously
described (Ionescu et al., 2001). Supershifts were performed with antibodies
specific for Sox and Fox family members from Santa Cruz Biotechnologies:
anti-Sox5a (sc-20091x), anti-Sox5b(sc-17329x), anti-Sox6a(sc-17332x),
anti-Sox13a(sc-20009x), anti-Sox13b(sc-17349x), anti-Sox13c(sc-17350x),
anti-Sox9a(sc-20095x), anti-Sox9b(sc-17340x), anti-Sox9c(sc-17341x), anti-
FoxA1(sc-22841x), anti-FoxA2(sc-6554x).
Immunofluorescence
Chondrocytes were fixed in 2% paraformaldehyde for 15 min at room temper-
ature, permeabilized with 0.25% Triton X-100, blocked in donkey serum and
then incubated with primary antibodies: 1:500 goat anti-Sox5 (Santa Cruz,
sc-20091x) and 1:50 mouse anti-collagen X (Developmental Studies
Hybridoma Bank, X-AC9). The interaction was then visualized using 1:250
anti-goat-FITC and anti-mouse-TRITC from Jackson Labs.
Analysis of Mutant Mice
For FoxA2-CreERT2; ROSA26 and FoxA3-Cre; ROSA26 mice, whole mount
beta-galactosidase staining was performed using a beta-galactosidase
detection kit from Millipore. Alcian Blue-Alizarin Red staining of the Col2-Cre;
FoxA2fl/fl; FoxA3/ skeletons was performed as previously described (De-
pew, 2008). For immunohistochemistry, E19.5 embryos were fixed in 4% buff-
ered paraformaldehyde overnight at 4C, paraffin-embedded and sectioned at
7 mm, and stained with hematoxylin and eosin from Richard Allen Scientific.
Von Kossa staining was performed using a ‘‘Von Kossa method for Calcium’’
kit from Polysciences according to manufacturer’s protocol. Alkaline phos-
phatase staining was performed using NBT/BCIP (Roche). Nonradioactive
in situ hybridization was performed as previously described (Kolpakova-Hart
et al., 2008).
Supplemental Experimental Procedures
Details of the construction of plasmids and viruses, RNA isolation and
RT-PCR, and generation of mutant mice are provided in the Supplement
Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and Supplemental
Experimental Procedures and can be found with this article online at
doi:10.1016/j.devcel.2012.03.011.
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